Work

The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes

Year: 2021

Type: article

Abstract: Multigene expression assays are prognostic for recurrence in hormone-receptor positive 2 (HER-2) negative breast cancer, and, in some cases, predictive of benefit from chemotherapy or extended endocrine therapy. The results of these assays may be used to guide treatment recommendations for early HER-2 negative breast cancer. We review the results of trials establishing the clinical utility of several commercially available gene expression assays.

Source: Therapeutic Advances in Medical Oncology

DOI: 10.1177/17588359211038467

Authors: Mali Barbi, Della Makower, Joseph A. Sparano

Institutions: Albert Einstein College of Medicine, Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center, Icahn School of Medicine at Mount Sinai

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,400